Heterogeneous copper concentrations in cancerous human prostate tissues

Denoyer, Delphine, Clatworthy, Sharnel A.S., Masaldan, Shashank, Meggyesy, Peter M. and Cater, Michael A. 2015, Heterogeneous copper concentrations in cancerous human prostate tissues, Prostate, vol. 75, no. 14, pp. 1510-1517, doi: 10.1002/pros.23022.

Attached Files
Name Description MIMEType Size Downloads

Title Heterogeneous copper concentrations in cancerous human prostate tissues
Author(s) Denoyer, DelphineORCID iD for Denoyer, Delphine orcid.org/0000-0001-8932-5116
Clatworthy, Sharnel A.S.
Masaldan, ShashankORCID iD for Masaldan, Shashank orcid.org/0000-0003-4960-4983
Meggyesy, Peter M.
Cater, Michael A.
Journal name Prostate
Volume number 75
Issue number 14
Start page 1510
End page 1517
Total pages 8
Publisher Wiley
Place of publication London, Eng.
Publication date 2015-10-01
ISSN 0270-4137
Summary © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc. Background Therapeutics that target copper for the treatment of prostate cancer are being evaluated in human clinical trials. Elevated intracellular copper is considered to sensitize prostate cancer cells to certain copper-coordination compounds, especially those with ionophoric properties. While there is compelling in vitro evidence that prostate cancer cells accumulate intracellular copper, a corresponding status for copper in patient tissues has not been corroborated. We therefore established whether copper concentrations increase in cancerous prostate tissues, and in sera, in patients throughout disease progression. Methods Human prostate tissue samples were obtained from patient prostatectomies (n=28), and together with patient-matched sera, were analyzed for copper content by inductively coupled plasma mass spectrometry. Results When grouped together, cancerous prostate tissues exhibiting moderate disease severity (Gleason Score 7) (n=10) had 1.6-fold more copper than age-matched normal tissues (n=10) (P<0.05). Those with more aggressive disease (Gleason Score 9) (n=8) had 1.8-fold more copper (P<0.05). In both disease stages however, the copper concentrations between individual samples were rather variable (0.55-3.02μg/g), with many clearly within the normal range (0.52-1.28μg/g). Additionally, we found that there was no change in serum copper concentrations in patients with either moderate or aggressive prostate cancer (Gleason Score 7 or 9), compared with reference intervals and to age-matched controls. Conclusions The heterogeneous nature of copper concentrations in cancerous prostate tissues, suggest that a small subset of patients may respond to treatments that target elevated intratumoral copper. Therefore, such approaches would likely require personalized treatment strategies. Prostate 75:1510-1517, 2015.
Language eng
DOI 10.1002/pros.23022
Field of Research 111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy)
111201 Cancer Cell Biology
111207 Molecular Targets
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Wiley Periodicals
Persistent URL http://hdl.handle.net/10536/DRO/DU:30078001

Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in TR Web of Science
Scopus Citation Count Cited 5 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 122 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Thu, 03 Dec 2015, 14:35:56 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.